[go: up one dir, main page]

MX2019006379A - Induccion de gen de trail de molecula pequeña en celulas normales y tumorales como una terapia anticancer. - Google Patents

Induccion de gen de trail de molecula pequeña en celulas normales y tumorales como una terapia anticancer.

Info

Publication number
MX2019006379A
MX2019006379A MX2019006379A MX2019006379A MX2019006379A MX 2019006379 A MX2019006379 A MX 2019006379A MX 2019006379 A MX2019006379 A MX 2019006379A MX 2019006379 A MX2019006379 A MX 2019006379A MX 2019006379 A MX2019006379 A MX 2019006379A
Authority
MX
Mexico
Prior art keywords
normal
tumor cells
small molecule
anticancer therapy
gene induction
Prior art date
Application number
MX2019006379A
Other languages
English (en)
Other versions
MX379539B (es
Inventor
E Allen Joshua
S El-Deiry Wafik
Sheng Wu Gen
Original Assignee
Penn State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47068061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019006379(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Penn State Res Found filed Critical Penn State Res Found
Publication of MX2019006379A publication Critical patent/MX2019006379A/es
Publication of MX379539B publication Critical patent/MX379539B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen métodos y composiciones que se relacionan a TIC10 de acuerdo a aspectos de la presente invención. Las composiciones y métodos tienen utilidad para tratar enfermedad, particularmente cáncer en un sujeto en necesidad del mismo, incluyendo un sujeto humano así como también sujetos de otras especies. Las composiciones tienen utilidad para tratar cáncer de cerebro en un sujeto en necesidad del mismo.
MX2019006379A 2011-04-29 2012-04-30 Induccion de gen de trail de molecula pequeña en celulas normales y tumorales como una terapia anticancer. MX379539B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161480743P 2011-04-29 2011-04-29
PCT/US2012/035831 WO2012149546A2 (en) 2011-04-29 2012-04-30 Small molecule trail gene induction by normal and tumor cells as an anticancer therapy

Publications (2)

Publication Number Publication Date
MX2019006379A true MX2019006379A (es) 2019-09-04
MX379539B MX379539B (es) 2025-03-11

Family

ID=47068061

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013012346A MX365365B (es) 2011-04-29 2012-04-30 Induccion de gen de trail de molécula pequeña en células normales y tumorales como una terapia anticáncer.
MX2019006379A MX379539B (es) 2011-04-29 2012-04-30 Induccion de gen de trail de molecula pequeña en celulas normales y tumorales como una terapia anticancer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013012346A MX365365B (es) 2011-04-29 2012-04-30 Induccion de gen de trail de molécula pequeña en células normales y tumorales como una terapia anticáncer.

Country Status (18)

Country Link
US (9) US8673923B2 (es)
EP (3) EP2701708B1 (es)
JP (7) JP6132833B2 (es)
CA (1) CA2832342C (es)
CY (1) CY1123010T1 (es)
DK (2) DK3679934T3 (es)
ES (2) ES2992934T3 (es)
FI (2) FI4335511T3 (es)
HR (2) HRP20241214T1 (es)
HU (2) HUE068623T2 (es)
LT (2) LT3679934T (es)
MX (2) MX365365B (es)
PL (2) PL3679934T3 (es)
PT (2) PT2701708T (es)
RS (2) RS60186B1 (es)
SI (2) SI3679934T1 (es)
SM (2) SMT202000272T1 (es)
WO (1) WO2012149546A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2992934T3 (en) 2011-04-29 2024-12-19 Penn State Res Found Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
SG11201507247WA (en) * 2013-03-13 2015-10-29 Oncoceutics Inc Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
WO2015073072A1 (en) * 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
CN110669047A (zh) 2013-11-15 2020-01-10 昂克希尔迪克斯有限公司 用于治疗癌症的化合物、其组合物及应用方法
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
US11299528B2 (en) 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
SI3662910T1 (sl) 2014-03-31 2025-05-30 The Scripps Research Institute Farmakofor za induciranje TRAIL
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
SI3805222T1 (sl) 2015-01-30 2025-04-30 Oncoceutics, Inc. Derivati 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-heksahidroimidazo[1,2-a] pirido[3,4-e]pirimidin-5(1H)-ona, njihove soli in njihova uporaba v terapiji
CA2978109A1 (en) 2015-03-31 2016-10-06 The University Of North Carolina At Chapel Hill Delivery vehicles for stem cells and uses thereof
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
ES3013312T3 (en) 2015-12-17 2025-04-11 Univ Johns Hopkins Ameliorating systemic sclerosis with death receptor agonists
SG11201806401YA (en) 2016-01-29 2018-08-30 Oncoceutics Inc G protein-coupled receptor (gpcr) modulation by imipridones
EP3439687A1 (en) 2016-04-07 2019-02-13 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
AU2023320122A1 (en) 2022-08-05 2025-02-20 Chimerix, Inc. Pharmaceutical compositions and uses thereof for the treatment of glioma
WO2024102447A1 (en) * 2022-11-10 2024-05-16 Emory University Uses of hydroimidazopyridopyrimidinone derivatives for managing aneurysms or other vascular conditions or diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA105008A (en) 1907-02-06 1907-04-30 Charles B. Grimshaw Self-closing valve
DE2150062A1 (de) * 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
US5648097A (en) 1995-10-04 1997-07-15 Biotek, Inc. Calcium mineral-based microparticles and method for the production thereof
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
ES2357225T3 (es) * 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
WO2003055489A1 (en) 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
BRPI0620695A2 (pt) * 2005-12-16 2011-11-22 Genentech, Inc método para tratar um tumor do tipo glioma, métodos de prognóstico e/ou diagnóstico de glioma, método de monitoramento ou diagnóstico, método para inibir o tamanho ou crescimento de um tumor do tipo glioma, métodos para tratar terapeuticamente, método para determinar o nìvel de expressão de marcadores determinantes de glioma ("gdm") de pn, prolif ou mes, método para prognosticar o tempo de sobrevida, método para diagnosticar a severidade de um tumor do tipo glioma e uso
WO2007090794A1 (en) 2006-02-10 2007-08-16 Nerviano Medical Sciences S.R.L. Combinations comprising a cdk inhibitor and a growth factor antibody or anti-mitotic
US20080004286A1 (en) 2006-06-30 2008-01-03 Schering Corporation Method of Using Substituted Piperidines that Increase P53 Activity
ES2415907T3 (es) * 2008-07-24 2013-07-29 Nerviano Medical Sciences S.R.L. Combinación terapéutica que comprende un inhibidor de cinasas aurora y agentes antiproliferativos
PE20120559A1 (es) * 2009-06-24 2012-05-21 Stephen Evans-Freke Composicion que comprende al factor liberador de corticotropina
ES2992934T3 (en) 2011-04-29 2024-12-19 Penn State Res Found Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
SG11201507247WA (en) 2013-03-13 2015-10-29 Oncoceutics Inc Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one

Also Published As

Publication number Publication date
WO2012149546A3 (en) 2013-01-03
CA2832342A1 (en) 2012-11-01
EP2701708B1 (en) 2020-01-22
CA2832342C (en) 2019-12-31
EP3679934A1 (en) 2020-07-15
US20220288079A1 (en) 2022-09-15
HUE068623T2 (hu) 2025-01-28
US20170224690A1 (en) 2017-08-10
ES2992934T3 (en) 2024-12-19
EP3679934B1 (en) 2024-06-05
HUE049207T2 (hu) 2020-09-28
JP2014514326A (ja) 2014-06-19
SI2701708T1 (sl) 2020-07-31
RS60186B1 (sr) 2020-06-30
FI4335511T3 (fi) 2026-01-29
PL2701708T3 (pl) 2020-11-02
SMT202400421T1 (it) 2024-11-15
US20140248264A1 (en) 2014-09-04
US20240415841A1 (en) 2024-12-19
CY1123010T1 (el) 2021-10-29
EP2701708A2 (en) 2014-03-05
LT2701708T (lt) 2020-05-25
US20120276088A1 (en) 2012-11-01
SMT202000272T1 (it) 2020-07-08
JP2025159099A (ja) 2025-10-17
JP2023060196A (ja) 2023-04-27
JP2016199580A (ja) 2016-12-01
US8673923B2 (en) 2014-03-18
US20150265619A1 (en) 2015-09-24
USRE46290E1 (en) 2017-01-31
US20170000790A1 (en) 2017-01-05
JP2019019145A (ja) 2019-02-07
HRP20200636T1 (hr) 2020-07-10
JP2021185210A (ja) 2021-12-09
US12036223B2 (en) 2024-07-16
FI3679934T3 (fi) 2024-07-08
US9452165B2 (en) 2016-09-27
DK3679934T3 (en) 2024-07-22
JP2024051080A (ja) 2024-04-10
EP4335511A3 (en) 2024-05-15
EP4335511A2 (en) 2024-03-13
DK2701708T3 (da) 2020-04-27
JP7600286B2 (ja) 2024-12-16
WO2012149546A2 (en) 2012-11-01
ES2786033T3 (es) 2020-10-08
SI3679934T1 (sl) 2025-04-30
MX365365B (es) 2019-05-30
JP6132833B2 (ja) 2017-05-24
US9061032B2 (en) 2015-06-23
LT3679934T (lt) 2024-11-11
MX379539B (es) 2025-03-11
US20150202206A1 (en) 2015-07-23
US9072744B1 (en) 2015-07-07
MX2013012346A (es) 2014-08-22
HRP20241214T1 (hr) 2024-11-22
EP2701708A4 (en) 2015-01-07
PL3679934T3 (pl) 2025-01-07
PT2701708T (pt) 2020-05-08
EP4335511B1 (en) 2025-11-26
US9629842B2 (en) 2017-04-25
PT3679934T (pt) 2024-09-05
RS65813B1 (sr) 2024-08-30

Similar Documents

Publication Publication Date Title
MX2019006379A (es) Induccion de gen de trail de molecula pequeña en celulas normales y tumorales como una terapia anticancer.
MY171561A (en) Conjugates for treating diseases caused by psma expressing cells
GT201500051A (es) Inhibidores de glucosilceramida sintasa
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
MX2014002990A (es) Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf.
MX358517B (es) Métodos para determinar eficacia de fármacos usando proteínas asociadas a cereblon.
BR112014031421A2 (pt) composições para tratamento de câncer e métodos para produção das mesmas
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
EA201590998A1 (ru) СВЯЗЫВАЮЩИЕСЯ С EGFR И c-Met МОЛЕКУЛЫ С ДОМЕНАМИ ФИБРОНЕКТИНА ТИПА III
ECSP13012572A (es) Análogos de nucleótidos sustituidos
MX384023B (es) Tratamiento de mielosupresion.
EA201500314A1 (ru) Лекарственные формы энзалутамида
CO7180225A2 (es) Tratamientos de combinación para melanoma que comprenden la administración de cobimetinib y vemurafenib
TW201611843A (en) Methods of treatment with arginine deiminase
MX363541B (es) Anticuerpos humanos para gfr alfa 3 y métodos para su uso.
EA201790032A1 (ru) Бициклически замещённые урацилы и их применение
EP2555627A4 (en) METHOD FOR TREATING CARCINOMA
GT201500071A (es) Antiandrògenos para el tratamiento del cancer de prostata residente a la castracion no metastàsico3
MX2015003701A (es) Composiciones para tratamiento.
MX2015016120A (es) Moleculas de union que se adhieren al factor de complemento c2 humano y usos de los mismos.
MX2015007719A (es) Terapia dirigida del receptor del factor de crecimiento epidermico (egfr) de trastornos neurologicos y dolor.
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
EA201400012A1 (ru) Нацеленная на egfr терапия
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291
PH12015501198A1 (en) Uses of bacopa monnieri extract